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Abstract
Background. Previous results have been mixed regarding the role of the apolipoprotein E e4
(APOE e4) allele in later-life depression: some studies note that carriers experience greater
symptoms and increased risk while others find no such association. However, there are few
prospective, population-based studies of the APOE e4-depression association and fewer that
examine depressive symptom trajectory and depression risk longitudinally. We examined
the association between APOE e4 allele status and longitudinal change in depressive symp-
toms and depression risk in later-life, over a 12-year follow-up period.
Methods. We used data from 690 participants of the Lothian Birth Cohort 1936 who took
part in the Scottish Mental Survey 1947 (aged 11) and were followed-up in later-life over
five waves from 2004 to 2019 (aged 70–82). We used APOE e4 allele status to predict longi-
tudinal change in depressive symptom scores and risk of depression (defined by a symptom
score threshold or use of depression-related medication). Models were adjusted for sex, child-
hood cognitive ability, childhood social class, education, adult social class, smoking status and
functional limitations at baseline.
Results. Depressive symptom scores increased with age. Once adjusted for covariates, APOE
e4 allele status did not significantly predict symptom score trajectories or depression risk.
Greater functional limitations at baseline significantly predicted poorer symptom score trajec-
tories and increased depression risk (defined by medications). APOE e4 allele status did not
significantly moderate the contribution of sex, education or functional limitations.
Conclusions. There was no evidence that APOE e4 carriers experience an increased risk for
later-life depression.
Introduction
The apolipoprotein E e4 (APOE e4) allele plays an important role in the onset of dementia
(Corder et al., 1993; Verghese, Castellano, & Holtzman, 2011) and the cognitive decline com-
monly observed across later-life (Davies et al., 2015, 2014; Deary et al., 2002; Luciano et al.,
2009). In particular, the APOE e4 allele is associated with the impaired maintenance of myelin
(Bartzokis et al., 2006) and beta-amyloid metabolism (Morris et al., 2010). However, APOE e4
is notably pleiotropic (Tuminello & Han, 2011), and has been implicated in several other later-
life outcomes such as increased cardiovascular risk (Song, Stampfer, & Liu, 2004).
However, there is growing evidence that APOE e4 is particularly important for later-life
depression. For example, in a meta-analysis of primarily candidate gene studies, Tsang and
colleagues reported that APOE e4 carriers had significantly higher odds of later-life depression
(clinical diagnosis or high symptom scores) (Tsang, Mather, Sachdev, & Reppermund, 2017),
although this was only relative to e3 allele carriers and was largely driven by a single candidate
gene study, with several other reviewed studies reporting no significant association. Despite
this, there have been relatively few attempts to examine the role of APOE e4 status in depres-
sion risk prospectively and among population-based samples. The few existing studies have
produced mixed findings, with some finding that APOE e4 carriers have greater depressive
symptoms and higher risk of later-life depression (Skoog et al., 2015) and others finding
less substantial (Burns, Andrews, Cherbuin, & Anstey, 2020) or non-significant (Locke
et al., 2013; Tully, Péres, Berr, & Tzourio, 2016) associations. APOE was also not identified
as a predictor of depression in two recent genome-wide association studies (Howard et al.,
2019; Wray et al., 2018).
In a recent study, Burns and colleagues examined associations between APOE e4 status and
depression over 12-year follow-up, both in terms of symptom scores and depression risk (iden-
tified by Brief Patient Health Questionnaire and Goldberg Depression Scale cut-offs)
(Goldberg, Bridges, Duncan-Jones, & Grayson, 1988; Kroenke, Spitzer, & Williams, 2001),
among participants of the Personality and Total Health (PATH) Through Life study (Burns
et al., 2020). In older adults aged 60–64 at baseline, Burns et al. noted that APOE e4 carriers
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experienced a significant although small increase in depression
symptom scores over the study period v. non-e4 carriers.
However, no corresponding increase was observed in the risk of
depression.
Given the mixed evidence regarding APOE e4 as a risk factor
for later-life depression, further research is needed to replicate
these findings. The current study examines the association between
APOE e4 status and both longitudinal change in depression symp-
tom scores and depression risk in the Lothian Birth Cohort 1936
(LBC1936), a large and representative sample of older adults with
over 12 years of longitudinal follow-up (Deary et al., 2007). We
also examine the contribution of a range of covariates and poten-
tial confounders from across the life course – including early-life
cognitive ability, socioeconomic circumstances and smoking status
– that are considered risk factors for depression in later-life
(Gilman, Kawachi, Fitzmaurice, & Buka, 2002; Lorant et al.,
2007; Lyness et al., 1998; Verropoulou, Serafetinidou, &
Tsimbos, 2019). Consistent with the most recent of previous
study (Burns et al., 2020), we hypothesise that depression symp-
tom scores will increase across later-life and that APOE e4 carriers
will experience a significantly greater increase than non-e4
carriers, independently of covariates such as sex and childhood
cognitive ability. In contrast, we hypothesise that there will be
no significant difference in depression risk – approximated using




The sample consisted of members of the Lothian Birth Cohort
1936 (LBC1936). These individuals were recruited from surviving
participants of the Scottish Mental Survey 1947 (The Scottish
Council for Research in Education, 1949) – a nationwide assess-
ment of cognitive ability given to almost all children attending
a Scottish school on the 4th June 1947 – who mostly still lived
in the Edinburgh City and surrounding Lothian area at study
commencement. The creation and design of the LBC1936 study
is described in more detail elsewhere (Deary et al., 2007; Deary,
Gow, Pattie, & Starr, 2012; Taylor, Pattie, & Deary, 2018). The
LBC1936 study is conducted with ethical approval from the
Research Ethics Committee for Scotland (wave 1: MREC/01/0/
56), the Lothian Research Ethics Committee (wave 1: LREC/
2003/2/29) and the Scotland a Research Ethics Committee
(waves 2–5: 07/MRE00/58), and in accordance with the
Declaration of Helsinki. Participants provided written informed
consent at each wave.
The current study used data from five waves of the LBC1936
study: wave 1 was collected in 2004–2007 (N = 1091, M age =
69.53 years), wave 2 was collected in 2007–2010 (n = 866,
M age = 72.49 years), wave 3 was collected in 2011–2013 (n =
697, M age = 76.25 years), wave 4 was collected in 2014–2017
(n = 550, M age = 79.32 years) and wave 5 was collected in
2017–2019 (n = 431, M age = 82.01 years). Individuals took part
in a median of four waves.
The analytic sample was formed according to the criteria
described by Burns et al. (2020). Notably, all participants in the
LBC1936 were white. We first removed individuals who did not
have genotyping data (n = 63), then individuals with Hospital
Anxiety and Depression Scale – Depression subscale scores of 8
or above at wave 1 (see below; n = 49), then individuals self-
reporting stroke at any wave (n = 121), and then individuals
with cognitive impairment at any wave (Mini Mental State
Examination scores <27; n = 168) (Folstein, Folstein, &
McHugh, 1975). This left an analytic sample of 690 individuals:
wave 1: N = 690, wave 2: N = 529, wave 3: N = 411, wave 4: N =
320, wave 5: N = 261 (median waves = 3).
Assessments
APOE
DNA was extracted from whole blood samples collected at wave
1. APOE alleles (e2, e3 or e4) were established by genotyping
the rs7412 and rs429358 single nucleotide polymorphisms with
TaqMan assays (Applied Biosystems, Carlsbad, CA, USA) at the
Wellcome Trust Clinical Research Facility Genetics Core,
Western General Hospital, Edinburgh. APOE genotype consists
of any two of the e2, e3 or e4 alleles, and has shown to be in
Hardy–Weinberg equilibrium for the LBC1936 ( p = 0.62)
(Luciano et al., 2009). A binary variable was created to indicate
the presence of an e4 allele.
Depression symptoms
At each of the five waves of follow-up, participants completed the
Hospital Anxiety and Depression Scale (HADS) (Zigmond &
Snaith, 1983), which asks participants about symptoms experi-
enced over the previous week. Total scores from the depression
subscale (scores’ range: 0–21) were used to measure depression
symptoms, with higher scores indicating more severe symptoms.
Depression risk
Two binary indicators of depression status were created for each
wave in order to measure depression risk. For the first indicator,
depression was defined as a HADS – Depression subscale total
score equal to or greater than 8. Previous study has shown this
cut-off to have good specificity (0.79) and sensitivity (0.9) for
depression (Bjelland, Dahl, Haug, & Neckelmann, 2002). For
the second indicator, depression was defined as the presence of
one or more keywords in the prescribed medications self-reported
by each individual (see online Supplementary material for a full
list of keywords). Individuals reported current medications as
part of a structured interview conducted at each wave. Note
that these indicator variables capture likely depression of any
type, including mixed presentations with anxiety or psychotic
symptoms, rather than pure depression.
Covariates
Covariates were chosen to align with those used by previous study
(Burns et al., 2020), with the addition of variables commonly used
in LBC1936 work. These covariates are commonly reported as
risk factors for later-life depression (Burns et al., 2020; Gilman
et al., 2002; Lorant et al., 2007; Lyness et al., 1998; Verropoulou
et al., 2019).
Sex and self-reported years spent in full-time education were
recorded at wave 1. Years of education was z-transformed prior
to analysis.
Physical health was measured using total score (max
possible = 18) on the Townsend Disability Scale (Townsend,
1962), completed at wave 1. Higher scores indicate more limited
functional health. Due to positive skew, total scores were trans-
formed using Tukey’s Ladder of Powers (Tukey, 1977), raising
scores to the power of 0.4.
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Childhood cognitive ability was measured using the total score
(max possible = 76) on the Moray House Test No. 12 (MHT),
completed in 1947 as part of the Scottish Mental Survey 1947
(The Scottish Council for Research in Education, 1949). Scores
were age-adjusted to account for the small differences in age at
MHT, and then IQ-transformed for analysis (M = 100, S.D. = 15).
Childhood and adulthood socioeconomic positions were using
measured using father’s occupation and own highest occupation
respectively, as retrospectively reported at wave 1. For women,
husband’s occupation was used where it was higher than their
own. Occupations were coded into one of five occupation social
classes (Professional, Managerial and Technical, Skilled,
Partly-Skilled and Unskilled) according to the 1950 United
Kingdom’s classification index (General Register Office, 1956).
The order of these classes was reversed so that higher-numbered
classes represented more professional occupations.
Participants reported lifetime smoking experience at wave 1. A
binary variable was created to indicate lifetime smoking status
(ever smoked v. never smoked).
Death was measured with both a binary indicator variable
(alive v. deceased) and age (in days) at death.
Statistical analyses
The analyses were intended to closely resemble those of previous
study (Burns et al., 2020).
Multilevel mixed effects models were constructed to examine
the association between APOE e4 allele status and longitudinal
change in depression symptom scores. Random intercepts and
slopes were included for each participant. The univariate contri-
bution of APOE e4 allele status was examined before adjusting
for sex, years of full-time education (z-score), Townsend
Disability Scale score (Tukey-transformed), age-adjusted MHT
score (IQ-scaled), father’s occupational social class (reversed),
own occupational social class (reversed) and smoking status.
Consistent with Burns et al., interaction effects were included
between APOE e4 allele status and sex, years of full-time educa-
tion and Townsend disability score (Burns et al., 2020).
Competing risks survival analyses were conducted to examine
the association between APOE e4 allele status and the risk of
depression across the follow-up period. In particular, we exam-
ined depression onset and death as competing risks; those indivi-
duals who die are no longer at risk of depression, and the APOE
e4 allele has been associated with other health conditions that
affect longevity (Ewbank, 2004; Song et al., 2004). Separate ana-
lyses were conducted using depression status derived from either
HADS-D clinical cut-off (scores ≥8) or from reported medica-
tions (depression-related medications; see online Supplementary
material). In both analyses, depression was not treated as a recur-
rent event, as the wave-based measurement of depression makes it
difficult to identify the start and end of depressive episodes. As
with the mixed effects analysis, the univariate contribution of
APOE e4 allele status was examined before adjusting for covari-
ates. No interaction effects or time-dependent covariates were
included. The proportional hazards assumption was met for
APOE e4 allele status ( p = 0.18) and for all included covariates
( ps > 0.10).
All analyses were conducted in R (R Core Team, 2018) using
RStudio (RStudio Team, 2016), and with the ‘lme4’ (Bates,
Mächler, Bolker, & Walker, 2015), ‘psych’ (Revelle, 2018), ‘sur-
vival’ (Therneau & Lumley, 2015) and ‘cmprsk’ (Gray, 2019)
packages. Models were not adjusted for multiple comparisons.
In order to assess whether results were partly driven by the spe-
cific categorisation of APOE e4 status, we additionally conducted
sensitivity analyses in which the mixed effects and competing
risks analyses were repeated using a binary APOE e4 status vari-
able that contrasts e4 allele carriers (e4/e4 and e3/e4) with e3/




Descriptive statistics for the analytic sample are shown in Table 1.
Compared to removed individuals, individuals included in the
analytic sample were significantly more likely to be female ( p <
0.01), report more years of education ( p < 0.01), be from higher
occupational social classes ( p < 0.001), report less functional
impairment ( p = 0.003), report fewer depressive symptoms at
each wave (wave 1: p < 0.001; wave 2: p < 0.001; wave 3: p <
0.001; wave 4: p = 0.01; wave 5: p < 0.001; Fig. 1) and be below
the depression cut-off (HADS Depression score p < 0.001; medi-
cations p = 0.02). Notably, individuals in the analytic sample did
not significantly differ from the removed individuals in terms of
APOE genotype distribution ( p = 0.08) or vitality status ( p =
0.62).
The analytic sample was predominantly female, well-educated
and reported few functional limitations. Roughly, a quarter (N =
180) of the analytic sample possessed an APOE e4 allele; the major-
ity of individuals possessed the e3/e3 genotype. The distribution of
APOE genotypes was in Hardy–Weinberg equilibrium (χ2 = 9.76, p
= 0.08). There was no evidence of differential dropout by APOE e4
status among the analytic sample after wave 1, with no significant
differences in the distribution of APOE genotypes (wave 2: p = 0.61;
wave 3: p = 0.75; wave 4: p = 0.73; wave 5: p = 0.52) or in the num-
ber of e4 alleles (wave 2: p = 0.98; wave 3: p = 0.44; wave 4: p = 0.35;
wave 5: p = 0.08) between those present or absent at each wave.
Furthermore, number of waves completed was not significantly
associated with APOE genotype ( p = 0.63) or number of e4 alleles
( p = 0.36). On average, very few depressive symptoms were
reported at each wave, although mean depression symptom scores
increased slightly with time. However, few individuals met either
the symptom score cut-off (HADS Depression scores ≥8; 5%) or
the medication cut-off (any depression-related prescription; 10%)
across the five-wave follow-up. In terms of overlap, eight
individuals met both cut-offs, 26 individuals met only the symptom
score cut-off (not the medication cut-off), 58 individuals met only
the medication cut-off (not the symptom score cut-off) and 598
individuals met neither cut-off.
APOE e4 and depression symptom scores
Visual inspection of the averaged HADS Depression score trajec-
tory, smoothed using Loess regression, suggested a linear increase
in scores over time (Fig. 1). Indeed, HADS Depression scores were
significantly predicted by wave (β = 0.04, S.E. = 0.01, p < 0.001) in a
linear growth model. Although scores were also significantly pre-
dicted by both a linear (β = 3.95, S.E. = 0.98, p < 0.001) and a quad-
ratic effect (β = 2.02, S.E. = 0.93, p = 0.03) of wave in an orthogonal
quadratic growth model, this model did not significantly improve
model fit relative to the linear growth model [linear growth
Akaike’s information criteria (AIC) = 7915.20, quadratic growth
AIC = 7915.20, χ = 8.04, df = 4, p = 0.09]. We therefore modelled
Psychological Medicine 3
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Table 1. Descriptives for the analytic sample (N = 690)
N (%) Mean (S.D.) N missing (%) Comparison with removed individuals p
Sex 0 (0%) <0.01
Male 323 (47%)
Female 367 (53%)
Full-time education (years) 0 (0%) <0.01
Mean (S.D.) 10.82 (1.14)
Father’s social class 66 (10%) 0.54
Unskilled 49 (7%)




Own social class 9 (1%) <0.001
Unskilled 0 (0%)




Moray House Test score (age-corrected) 30 (4%) 0.22
Mean (S.D.) 48.94 (2.26)
Townsend Disability Scale score 1 (0%) <0.01
Mean (S.D.) 0.84 (1.72)
Smoking status 0 (0%) 0.10
Never smoked 330 (48%)
Ever smoked 360 (52%)







HADS – Depression score wave 1 0 (0%) <0.001
Mean (S.D.) 2.40 (1.71)
HADS – Depression score wave 2 162 (23%) <0.001
Mean (S.D.) 2.36 (1.95)
HADS – Depression score wave 3 279 (40%) <0.001
Mean (S.D.) 2.52 (2.06)
HADS – Depression score wave 4 370 (54%) 0.01
Mean (S.D.) 2.68 (1.97)
HADS – Depression score wave 5 430 (62%) <0.001
Mean (S.D.) 2.67 (2.03)
Depressed status – HADS cut-off 0 (0%) <0.001
Never depressed 656 (95%)
(Continued )
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growth in HADS Depression scores as linear in further analyses.
In the univariate model, the APOE e4 allele was not significantly
associated with longitudinal change in HADS Depression scores
(Table 2). In the fully-adjusted model (Table 2), greater functional
limitations at baseline were significantly associated with an
increase in depressive symptomology over time. No other covari-
ate, including interaction effects, significantly predicted longitu-
dinal change in HADS Depression scores. A similar pattern of
associations was observed when using the e4 v. e3/e3 binary vari-
able (online Supplementary material).
APOE e4 and depression risk
When examining depression risk derived from the HADS
Depression score cut-off, individuals with the APOE e4 allele
were marginally less likely to experience depression over the
follow-up period (Table 2; Fig. 2a). However, this association did
not appear to be robust, and was attenuated in the fully-adjusted
model, where there were no significant predictors of depression
risk (Table 2). This pattern of results was similar when using the
e4 v. e3/e3 binary variable (online Supplementary material).
When examining depression risk derived from the medication
cut-off, individuals with the APOE e4 allele were not at signifi-
cantly increased risk across the follow-up period (Table 2). In
the fully-adjusted model, being female and greater functional lim-
itations were the only variables to significantly predict higher risk
of depression (Table 2). In sensitivity analysis, using the adjusted
e4 status variable, only greater functional limitations significantly
predicted depression risk (online Supplementary material).
We additionally examined depression risk derived from a com-
bination of the HADS Depression score and medication cut-offs,
with the earliest identified episode used to estimate survival time.
Individuals with the APOE e4 allele were not at significantly
increased risk of depression over the follow-up period in either
Table 1. (Continued.)
N (%) Mean (S.D.) N missing (%) Comparison with removed individuals p
Ever depressed 34 (5%)
Depressed status – Medication cut-off 0 (0%) 0.02
Never depressed 624 (90%)
Ever depressed 66 (10%)
Deceased status 0 (0%) 0.62
Alive 473 (69%)
Deceased 217 (31%)
p indicates comparison between the analytic sample (N = 690) and removed individuals (N = 401); Kruskal–Wallis tests are used for numeric variables and χ2 tests are used for categorical
variables.
Fig. 1. Individual longitudinal trajectories of HADS-Depression scores. The solid black line shows the mean trajectory (smoothed loess regression) with 95% con-
fidence intervals and the dashed black line shows the cut-off used. Note: The analytic sample only includes individuals with HADS-Depression scores <8 at baseline.
Waves 1–5 were measured at mean ages of 70, 72, 76, 79 and 83 years-old.
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the univariate or fully-adjusted models (Table 2). Increased risk of
depression in the fully-adjusted model was significantly predicted
by being female and by greater functional limitations (Table 2).
This pattern of results was similar when using the e4 v. e3/e3 bin-
ary variable (online Supplementary material).
Discussion
The current study aimed to add to the few longitudinal
population-based studies of the role of APOE in later-life depres-
sion and to extend previous study using a large, well-phenotyped
birth cohort.
The current study found no significant association between the
APOE e4 allele and longitudinal change in depressive symptoms
or longitudinal risk of depression, even when directly contrasting
e4 carriers to e3/e3 individuals (online Supplementary material).
These findings conflict with those from a Swedish population-
based sample of older adults (Skoog et al., 2015), although notably
the follow-up in the current study was more frequent. These find-
ings are also partly in conflict with those from the PATH Through
Life study, in which older adults with the APOE e4 allele experi-
enced a greater longitudinal increase in depressive symptoms than
those without the APOE e4 allele (incidence rate ratio = 1.130)
(Burns et al., 2020). However, due to the low number of
symptoms reported, Burns et al. concluded that this increase
among older adult APOE e4 carriers was not substantive or clin-
ically significant. The non-significant result observed here sup-
ports this interpretation (see also Locke et al., 2013; Tully et al.,
2016), although it is worth noting the smaller analytic sample
here (N = 690) v. the over 60s sample in Burns et al. (N = 1768)
(Burns et al., 2020). Consistent with recent longitudinal studies
(Burns et al., 2020; Locke et al., 2013) and with recent large
genome-wide association studies of broad depression phenotypes
using predominantly middle-aged adults (Howard et al., 2019;
Wray et al., 2018), the current study observed no significant
association between the APOE e4 allele and depression risk
once life-course covariates were accounted for.
The current study did find that HADS depression symptom
trajectories were significantly predicted by Townsend disability
scores around age 70; those with more functional limitations at
baseline experienced greater increases in depression symptom
scores over time. This is consistent with study showing that func-
tional limitations place an increasing burden on mental health
(Yang & George, 2005). Notably, functional limitations did not
appear to predict risk of later-life depression using the
HADS-Depression threshold, suggesting that the increase in
symptoms remained below clinical thresholds. We did not, how-
ever, account for functional limitations as a time-dependent
Table 2. Relationship between APOE e4 allele status – univariate and adjusted for covariates – and both longitudinal change in depressive symptom scores
(multilevel mixed effects regression) and depression risk (HADS – Depression cut-off, Medication cut-off and combined; competing risks regression)
HADS-Depression scores
Depression risk – HADS
cut-off
Depression risk -
Medication cut-off Depression risk – Combined
IRR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p
Univariate model
APOE e4 allele
status – e4 allele
0.98 (0.88–1.10) 0.76 0.35 (0.12–0.98) 0.05 1.15 (0.68–1.95) 0.60 0.88 (0.55–1.40) 0.58
Multivariate model
APOE e4 allele
status – e4 allele
1.03 (0.86–1.23) 0.75 0.50 (0.17–1.48) 0.21 1.17 (0.63–2.16) 0.62 0.97 (0.56–1.66) 0.91
Sex – female 0.99 (0.87–1.13) 0.92 1.92 (0.80–4.65) 0.15 2.14 (1.16–3.96) 0.02 1.93 (1.15–3.24) 0.01
Years of full-time
education (z-scaled)




1.38 (1.25–1.52) <0.001 1.43 (0.86–2.40) 0.17 1.76 (1.21–2.54) <0.01 1.70 (1.25–2.32) <0.001
Age-adjusted MHT
score (IQ-scaled)




1.00 (0.95–1.07) 0.88 0.85 (0.57–1.27) 0.42 0.92 (0.67–1.27) 0.63 0.88 (0.68–1.13) 0.31
Own occupational
social class (reversed)
0.94 (0.86–1.02) 0.15 0.69 (0.42–1.13) 0.14 0.92 (0.60–1.40) 0.69 0.88 (0.62–1.25) 0.48
Lifetime smoking
status – ever smoked
1.02 (0.91–1.13) 0.76 0.55 (0.25–1.20) 0.13 1.45 (0.84–2.51) 0.19 1.04 (0.65–1.65) 0.87
APOE e4 × Sex 0.97 (0.76–1.23) 0.77 – – – – – –
APOE e4 × Education 1.03 (0.92–1.16) 0.60 – – – – – –
APOE e4 ×
Townsend
0.91 (0.76–1.09) 0.32 – – – – – –
IRR, incidence rate ratio; OR, odds ratio; HADS, Hospital Anxiety and Depression Scale; MHT, Moray House Test No. 12.
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covariate or examine concurrent changes in disability and depres-
sion symptoms. It is possible that longitudinal (post-baseline)
changes in functional health may also contribute to depressive
symptom trajectories (Schieman & Plickert, 2007; Yang &
George, 2005). Although more functional limitations did predict
increased risk of depression measured by medication-use, several
of the medications included in the definition may be prescribed
for stress and pain, and so there is likely confounding with the
limiting condition itself.
The current study also observed that, although depressive
symptoms generally worsened with increasing age, overall scores
were relatively low. This is consistent with several previous studies
demonstrating that older adults generally exhibit fewer depressive
symptoms than younger or middle-aged adults (Burns et al., 2020;
Girling et al., 1995; Locke et al., 2013; Mauricio et al., 2000; Skoog
et al., 2015; Varma, 2012).
Limitations
Although we examined both longitudinal change in self-reported
depressive symptoms and proxy indicators of depression, clinical
diagnoses of depression were not available. The proxy indicators
were created to capture any depression, including both pure pre-
sentations of depression (i.e. those reporting only depressive
symptoms or only depression-related medications) and mixed
presentations with additional anxiety, psychosis or apathy.
Furthermore, we make no distinction between minor (i.e. where
symptoms are not sufficiently severe or are too few to warrant a
diagnosis of major depression) or major depression or between
acute and chronic depression. As clinically distinct conditions,
future research may benefit from examining the potentially differ-
ential role of APOE genotype in different presentations of depres-
sion, particularly given that previous study has suggested that
Fig. 2. Cumulative risk curves for depression (dashed lines), deceased (dotted lines) and censored (attrited or survived to end of follow-up without being recorded
as deceased or depressed; solid lines), split by APOE e4 allele status (e4 allele = black, no e4 allele = grey): (a) HADS-Depression score cut-off and (b) medication
cut-off. Note: At baseline participants did not report depression according to the HADS-Depression score cut-off. Waves 1–5 were measured at mean ages of 70, 72,
76, 79 and 83 years-old. Depression and censored status were assessed at each wave, whereas deceased status was assessed continuously.
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APOE e4 confers a greater risk of minor but not major depression
(Skoog et al., 2015).
Depression was not treated as a recurrent event in the analyses,
in part because it was measured in waves rather than continu-
ously. As there was roughly a 3-year gap between each wave, it
is possible that individuals may have experienced depressive epi-
sodes in between waves. Such episodes would not be captured by
the HADS questionnaire, which asks participants to rate how they
felt over the preceding week only, or by prescribed medication
self-reported at interview. Drop-out between waves may also
have indicated attrition of the most depressed individuals or
those most at risk for depression in later-life, resulting in an
underestimation of depression risk and symptom change. Note,
however, that depressive symptom scores increased slightly over
the study period, and that presence of the APOE e4 allele did
not predict death as a competing risk (HADS-Depression cut-off:
p = 0.140; medication cut-off: p = 0.520).
Finally, in terms of the sample, there were relatively few indi-
viduals identified as ‘depressed’ at any point in the follow-up per-
iod using the HADS-Depression cut-off (N = 34; 5%). Such a low
frequency may be partly explained by the narrow time window
(previous 1 week) assessed by the HADS questionnaire.
Although the medication cut-off did identify more individuals
as ‘depressed’ (N = 66; 10%) – more consistent with the rates
reported by previous study (11% in Burns et al., 2020) – indivi-
duals did not provide information about why these medications
were prescribed or at what dosage. Furthermore, those classified
as ‘depressed’ according to medications could have treated (i.e.
not incident) depression, whereas the HADS questionnaire
included only incident depression. The medication cut-off may
therefore be too sensitive, and the corresponding results inter-
preted with caution. Note that APOE e4 allele status did not sig-
nificantly predict depression risk using the medication cut-off.
Strengths
The current study represents one of the first attempts to examine
the role of APOE in later-life depression longitudinally among a
single-year birth cohort. Where previous studies have used age-
binned cohorts (e.g. 60s), significant associations may arise due
to the confounding effect of age. In addition, the LBC1936 is
one of the most extensively phenotyped birth cohorts, and pro-
vides the opportunity to account for a variety of important covari-
ates from across the life course (Deary et al., 2007). For example,
here functional limitations in older age were associated with
greater increases in depressive symptomology and increased risk
of later-life depression. The current study also represents the long-
est follow-up of older adults to date, with LBC1936 individuals
followed for over 12-years.
Conclusion
The current study is one of the largest longitudinal assessments of
the role of APOE e4 in later-life depression symptomology and
risk. We found no evidence for a greater increase in depressive
symptoms or a greater risk of depression among APOE e4 allele
carriers. This supports previous suggestions that older APOE e4
allele carriers are not at an increased risk for later-life depression.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0033291721000623
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